165 related articles for article (PubMed ID: 32514196)
21. Cost-effectiveness of treating multidrug-resistant tuberculosis.
Resch SC; Salomon JA; Murray M; Weinstein MC
PLoS Med; 2006 Jul; 3(7):e241. PubMed ID: 16796403
[TBL] [Abstract][Full Text] [Related]
22. Cost of treatment support for multidrug-resistant tuberculosis using patient-centred approaches in Ethiopia: a model-based method.
Rosu L; Morgan L; Tomeny EM; Worthington C; Jin M; Nidoi J; Worthington D
Infect Dis Poverty; 2023 Jul; 12(1):65. PubMed ID: 37420269
[TBL] [Abstract][Full Text] [Related]
23. Scaling up target regimens for tuberculosis preventive treatment in Brazil and South Africa: An analysis of costs and cost-effectiveness.
Nsengiyumva NP; Campbell JR; Oxlade O; Vesga JF; Lienhardt C; Trajman A; Falzon D; Den Boon S; Arinaminpathy N; Schwartzman K
PLoS Med; 2022 Jun; 19(6):e1004032. PubMed ID: 35696431
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
Wirth D; Dass R; Hettle R
BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
[TBL] [Abstract][Full Text] [Related]
25. Cost of multi drug resistance tuberculosis in Germany.
Diel R; Nienhaus A; Lampenius N; Rüsch-Gerdes S; Richter E
Respir Med; 2014 Nov; 108(11):1677-87. PubMed ID: 25443398
[TBL] [Abstract][Full Text] [Related]
26. Patients' costs associated with seeking and accessing treatment for drug-resistant tuberculosis in South Africa.
Ramma L; Cox H; Wilkinson L; Foster N; Cunnama L; Vassall A; Sinanovic E
Int J Tuberc Lung Dis; 2015 Dec; 19(12):1513-9. PubMed ID: 26614194
[TBL] [Abstract][Full Text] [Related]
27. Directly observed treatment for multidrug-resistant tuberculosis: an economic evaluation in the United States of America and South Africa.
Wilton P; Smith RD; Coast J; Millar M; Karcher A
Int J Tuberc Lung Dis; 2001 Dec; 5(12):1137-42. PubMed ID: 11769772
[TBL] [Abstract][Full Text] [Related]
28. Cost-optimization in the treatment of multidrug resistant tuberculosis in Nigeria.
Musa BM; John D; Habib AG; Kuznik A
Trop Med Int Health; 2016 Feb; 21(2):176-82. PubMed ID: 26610176
[TBL] [Abstract][Full Text] [Related]
29. A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis.
Fitzpatrick C; Floyd K
Pharmacoeconomics; 2012 Jan; 30(1):63-80. PubMed ID: 22070215
[TBL] [Abstract][Full Text] [Related]
30. Cost per patient of treatment for rifampicin-resistant tuberculosis in a community-based programme in Khayelitsha, South Africa.
Cox H; Ramma L; Wilkinson L; Azevedo V; Sinanovic E
Trop Med Int Health; 2015 Oct; 20(10):1337-45. PubMed ID: 25975868
[TBL] [Abstract][Full Text] [Related]
31. Cost effectiveness of treating multi-drug resistant tuberculosis by adding Deltyba™ to background regimens in Germany.
Diel R; Hittel N; Schaberg T
Respir Med; 2015 May; 109(5):632-41. PubMed ID: 25862597
[TBL] [Abstract][Full Text] [Related]
32. Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and Russia.
Floyd K; Hutubessy R; Kliiman K; Centis R; Khurieva N; Jakobowiak W; Danilovits M; Peremitin G; Keshavjee S; Migliori GB
Eur Respir J; 2012 Jul; 40(1):133-42. PubMed ID: 22362862
[TBL] [Abstract][Full Text] [Related]
33. Cost of digital technologies and family-observed DOT for a shorter MDR-TB regimen: a modelling study in Ethiopia, India and Uganda.
Rosu L; Madan J; Bronson G; Nidoi J; Tefera MG; Malaisamy M; Squire BS; Worrall E
BMC Health Serv Res; 2023 Nov; 23(1):1275. PubMed ID: 37980524
[TBL] [Abstract][Full Text] [Related]
34. Economic burden of multidrug-resistant tuberculosis: a multicenter study across Vietnamese regions.
Nam VX; Nhung NV; Hoa NB; Thuy HTT; Phuong NTM; Anh NT; Anh LTN; Trung VQ; Ha TV; Meeyai A; Thavorncharoensap M; Chaikledkaew U
Int J Tuberc Lung Dis; 2018 Aug; 22(8):912-917. PubMed ID: 29991401
[TBL] [Abstract][Full Text] [Related]
35. Cost effectiveness of decentralised care model for managing MDR-TB in India.
John D; Chatterjee P; Murthy S; Bhat R; Musa BM
Indian J Tuberc; 2018 Jul; 65(3):208-217. PubMed ID: 29933862
[TBL] [Abstract][Full Text] [Related]
36. Cost outcome analysis of decentralized care for drug-resistant tuberculosis in Johannesburg, South Africa.
van Rensburg C; Berhanu R; Hirasen K; Evans D; Rosen S; Long L
PLoS One; 2019; 14(6):e0217820. PubMed ID: 31170207
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of new MDR-TB regimens: study protocol for the TB-PRACTECAL economic evaluation substudy.
Sweeney S; Gomez G; Kitson N; Sinha A; Yatskevich N; Staples S; Moodliar R; Motlhako S; Maloma M; Rassool M; Ngubane N; Ndlovu E; Nyang'wa BT
BMJ Open; 2020 Oct; 10(10):e036599. PubMed ID: 33039989
[TBL] [Abstract][Full Text] [Related]
38. Tuberculosis: cost of illness in Germany.
Diel R; Rutz S; Castell S; Schaberg T
Eur Respir J; 2012 Jul; 40(1):143-51. PubMed ID: 22267754
[TBL] [Abstract][Full Text] [Related]
39. Can patients afford the cost of treatment for multidrug-resistant tuberculosis in Ethiopia?
Berhanu RH; Schnippel K; Kularatne R; Firnhaber C; Jacobson KR; Horsburgh CR; Lippincott CK
Int J Tuberc Lung Dis; 2018 Aug; 22(8):358-362. PubMed ID: 29991400
[TBL] [Abstract][Full Text] [Related]
40. Cost of multidrug resistant tuberculosis in Germany-An update.
Diel R; Sotgiu G; Andres S; Hillemann D; Maurer FP
Int J Infect Dis; 2021 Feb; 103():102-109. PubMed ID: 33157286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
